Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Goff

Showing results (431-440 of 527) with videos related to

Pageof 53
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 22, 2008
Association of arachidonate 12-lipoxygenase genotype variation and glycemic control with albuminuria in type 2 diabetesYongmei Liu, Barry I Freedman, Kathryn P Burdon, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
The American Journal of Psychiatry|May 3, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gainDavid C Henderson, Paul M Copeland, Tara B Daley, et al.
The American Journal of Cardiology|July 12, 2007
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDavid C Goff, Hertzel C Gerstein, Henry N Ginsberg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 14, 2017
Intermuscular Adipose Tissue and Subclinical Coronary Artery Calcification in Midlife: The CARDIA Study (Coronary Artery Risk Development in Young Adults)James G Terry, Christina M Shay, Pamela J Schreiner, et al.
Schizophrenia Bulletin|November 12, 2022
Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode SchizophreniaWei Qi, Julia Marx, Michael Zingman, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Human Psychopharmacology|March 14, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophreniaDavid C Henderson, Xiaoduo Fan, Paul M Copeland, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|March 11, 2004
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT studyJoshua I Barzilay, Barry R Davis, Judy Bettencourt, et al.
Schizophrenia Research|October 4, 2005
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsDonald C Goff, Lisa M Sullivan, Joseph P McEvoy, et al.
Pageof 53

Showing results (431-440 of 527) with videos related to

Sort By:
Pageof 53
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 22, 2008
Association of arachidonate 12-lipoxygenase genotype variation and glycemic control with albuminuria in type 2 diabetesYongmei Liu, Barry I Freedman, Kathryn P Burdon, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
The American Journal of Psychiatry|May 3, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gainDavid C Henderson, Paul M Copeland, Tara B Daley, et al.
The American Journal of Cardiology|July 12, 2007
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDavid C Goff, Hertzel C Gerstein, Henry N Ginsberg, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 14, 2017
Intermuscular Adipose Tissue and Subclinical Coronary Artery Calcification in Midlife: The CARDIA Study (Coronary Artery Risk Development in Young Adults)James G Terry, Christina M Shay, Pamela J Schreiner, et al.
Schizophrenia Bulletin|November 12, 2022
Hippocampal Subfield Volumes Predict Disengagement from Maintenance Treatment in First Episode SchizophreniaWei Qi, Julia Marx, Michael Zingman, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Human Psychopharmacology|March 14, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophreniaDavid C Henderson, Xiaoduo Fan, Paul M Copeland, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|March 11, 2004
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT studyJoshua I Barzilay, Barry R Davis, Judy Bettencourt, et al.
Schizophrenia Research|October 4, 2005
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsDonald C Goff, Lisa M Sullivan, Joseph P McEvoy, et al.
Pageof 53